COVID-19 put into perspective the importance of the pharma industry to the global economy. Goodwin London Life Sciences partner Andrew Harrow reflects on 2020’s impact on the pharma sector, particularly biotech, and discusses what 2021 might look like for industry deals and investment. Full article here.
